Pages that link to "Q35146081"
Jump to navigation
Jump to search
The following pages link to Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia (Q35146081):
Displaying 39 items.
- Role of the tumor microenvironment in mature B-cell lymphoid malignancies (Q26748775) (← links)
- Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date (Q26798062) (← links)
- Lenalidomide and chronic lymphocytic leukemia (Q26823597) (← links)
- Targeted therapies in CLL: mechanisms of resistance and strategies for management (Q27002528) (← links)
- Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints (Q33436535) (← links)
- Lenalidomide enhances anti-myeloma cellular immunity (Q33903133) (← links)
- Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia (Q34008584) (← links)
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia (Q34009041) (← links)
- Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. (Q34278096) (← links)
- Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases (Q36193863) (← links)
- Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases (Q36212618) (← links)
- Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer (Q36252792) (← links)
- CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma (Q36546548) (← links)
- Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia (Q36929831) (← links)
- Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics (Q37427107) (← links)
- Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes (Q38008379) (← links)
- Lenalidomide alone and in combination for chronic lymphocytic leukemia (Q38068736) (← links)
- Regulatory T cells in allogeneic stem cell transplantation (Q38112114) (← links)
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment (Q38550810) (← links)
- Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma (Q38898226) (← links)
- Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature. (Q39044809) (← links)
- Molecular action of lenalidomide in lymphocytes and hematologic malignancies (Q39570166) (← links)
- Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. (Q40438184) (← links)
- Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant (Q40493612) (← links)
- Trial Watch: Lenalidomide-based immunochemotherapy (Q42737828) (← links)
- Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? (Q42981057) (← links)
- Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia (Q43596419) (← links)
- Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. (Q46319985) (← links)
- Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. (Q46517344) (← links)
- Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies (Q49704420) (← links)
- Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q. (Q51579894) (← links)
- Lenalidomide potentiates CD4 CD25 Treg-related suppression of lymphoma B-cell proliferation. (Q53152345) (← links)
- Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia (Q57807709) (← links)
- Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients (Q58552961) (← links)
- Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia (Q60922704) (← links)
- Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia (Q60959923) (← links)
- Multiple myeloma and immunomodulation: regulating the regulatory cells (Q83590483) (← links)
- HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy (Q88312666) (← links)
- Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role (Q89896570) (← links)